Biochemical response and integrated traditional Chinese and Western medicine therapy for primary biliary cholangitis

Wang XiaoJing; Liu Yao; Wang XianBo

doi:10.3969/j.issn.1001-5256.2020.01.004

Volume 36 Issue 1

Jan. 2020

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2020 > 36(1): 26-30

PDF( 2123 KB)

Biochemical response and integrated traditional Chinese and Western medicine therapy for primary biliary cholangitis

DOI: 10.3969/j.issn.1001-5256.2020.01.004

Department of Integrative Medicine,Beijing Ditan Hospital,Capital Medical University

Research funding:

Received Date: 2019-12-20
Published Date: 2020-01-20

Abstract

Abstract

Primary biliary cholangitis(PBC) is an immune-mediated chronic and progressive intrahepatic cholestasis disease. Treatment with ursodeoxycholic acid(UDCA) can significantly improve the prognosis of patients with PBC,but some patients still have poor response to UDCA,which is the main risk factor for disease progression. Several evaluation models and scoring systems based on biochemical response have been applied to screen out patients with poor response in clinical practice. Integrated traditional Chinese and Western medicine therapy for PBC has certain advantages in improving the symptoms,liver biochemistry,fibrosis indices,and biochemical response rate of PBC patients and thus holds promise for clinical application; however,further improvement is needed for experimental design and efficacy evaluation.
- primary biliary cholangitis,
- biochemical response,
- TCM WM therapy

FullText(HTML)

References(40)

References

[1] Chinese Society of Hepatology,Chinese Medical Association;Chinese Society of Gastroenterology,Chinese Medical Association; Chinese Society of Infectious Diseases,Chinese Medical Association. Consensus on the diagnosis and management of primary biliary cirrhosis(cholangitis)(2015)[J]. J Clin Hepatol,2015,31(12):1980-1988.(in Chinese)中华医学会肝病学分会，中华医学会消化病学分会，中华医学会感染病学分会．原发性胆汁性肝硬化(又名原发性胆汁性胆管炎)诊断和治疗共识(2015)[J]．临床肝胆病杂志，2015,31(12):1980-1988.

[2] LINDOR KD,BOWLUS CL,BOYER J,et al. Primary biliary cholangitis:2018 practice guidance from the American Association for the Study of Liver Diseases[J]. Hepatology,2019,69(1):394-419.

[3] HIRSCHFIELD GM,DYSON JK,ALEXANDER GJM,et al. The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines[J]. Gut,2018,67(9):1568-1572.

[4] European Association for the Study of the Liver. EASL Clinical Practice Guidelines:The diagnosis and management of patients with primary biliary cholangitis[J]. J Hepatol,2017,67(1):145-172.

[5] HARMS MH,LAMMERS WJ,THORBURN D,et al. Major hepatic complications in ursodeoxycholic acid-treated patients with primary biliary cholangitis:Risk factors and time trends in incidence and outcome[J]. Am J Gastroenterol,2018,113(2):254-264.

[6] CARBONE M,MELLS GF,PELLS G,et al. Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid[J]. Gastroenterology,2013,144(3):560-569.

[7] MARSCHALL HU,HENRIKSSON I,LINDBERG S,et al. Incidence,prevalence,and outcome of primary biliary cholangitis in a nationwide Swedish population-based cohort[J]. Scientific reports,2019,9(1):11525.

[8] CHEN S,DUAN W,LI M,et al. Prognosis of 732 ursodeoxycholic acid-treated patients with primary biliary cholangitis:A single center follow-up study from China[J]. J Gastroenterol Hepatol,2019,34(7):1236-1241.

[9] CHEUNG AC,LAMMERS WJ,MURILLO PEREZ CF,et al.Effects of age and sex of response to ursodeoxycholic acid and transplant-free survival in patients with primary biliary cholangitis[J]. Clin Gastroenterol Hepatol,2019,17(10):2076-2084.

[10] YOO JJ,CHO EJ,LEE B,et al. Prognostic value of biochemical response models for primary biliary cholangitis and the additional role of the neutrophil-to-lymphocyte ratio[J]. Gut Liver,2018,12(6):714-721.

[11] CHEUNG KS,SETO WK,FUNG J,et al. Prognostic factors for transplant-free survival and validation of prognostic models in chinese patients with primary biliary cholangitis receiving ursodeoxycholic acid[J]. Clin Transl Gastroenterol,2017,8(6):e100.

[12] HUANG C,HAN W,WANG C,et al. Early prognostic utility of Gp210 antibody-positive rate in primary biliary cholangitis:A meta-analysis[J]. Disease markers,2019,2019:9121207.

[13] NAKAMURA M,KOMORI A,ITO M,et al. Predictive role of anti-gp210 and anticentromere antibodies in long-term outcome of primary biliary[J]. Hepatol Res,2007,37(3):412-419.

[14] TAKANO K,SAEKI C,OIKAWA T,et al. IgM response is a prognostic biomarker of primary biliary cholangitis treated with ursodeoxycholic acid and bezafibrate[J]. J Gastroenterol Hepatol,2019.[Epub ahead of print]

[15] MURILLO PEREZ CF,HIRSCHFIELD G,CORPECHOT C,et al. Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response[J]. Aliment Pharmacol Ther,2019,50(10):1127-1136.

[16] LIU X,XU H,ZHAN M,et al. The potential effects of diabetes mellitus on liver fibrosis in patients with primary biliary cholangitis[J]. Med Sci Monit,2019,25:6174-6180.

[17] NI P,MEN R,SHEN M,et al. Concomitant Sjgren’s syndrome was not associated with a poorer response or outcomes in ursodeoxycholic acid-treated patients with primary biliary cholangitis[J]. Can J Gastroenterol Hepatol,2019,2019:7396870.

[18] ANGULO P,DICKSON ER,THERNEAU TM,et al. Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis:A randomized trial[J]. J Hepatol,1999,30(5):830-835.

[19] CORPECHOT C,CARRAT F,POUJOL-ROBERT A,et al.Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis[J].Hepatology,2012,56(1):198-208.

[20] LAMMERS WJ,HIRSCHFIELD GM,CORPECHOT C,et al.Development and validat ion of a scoring system to predict outcomesof patients with primary biliary cirrhosis receiving ursodeox ycholic acid therapy[J]. Gastroenterology,2015,149(7):1804-1812.

[21] CARBONE M,SHARP SJ,FLACK S,et al. The UKPBC risk scores:Derivation and validat ion of a scoring system for long-term prediction of end-stage liver disease in primary biliary cirrhosis[J]. Hepatology,2016,63(3):930-950.

[22] EFE C,TA爦ILAR K,HENRIKSSON I,et al. Validation of risk scoring systems in ursodeoxycholic acid-treated patients with primary biliary cholangitis[J]. Am J Gastroenterol,2019,114(7):1101-1108.

[23] CHEN J,XUE D,GAO F,et al. Influence factors and a predictive scoring model for measuring the biochemical response of primary biliary cholangitis to ursodeoxycholic acid treatment[J]. Eur J Gastroenterol Hepatol,2018,30(11):1352-1360.

[24] HIRSCHFIELD GM,MASON A,LUKETIC V,et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid[J]. Gastroenterology,2015,148(4):751-761.

[25] KOWDLEY KV,LUKETIC V,CHAPMAN R,et al. A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis[J]. Hepatology,2018,67(5):1890-1902.

[26] CHEN JL,YANG X,ZHANG Q,et al. Effect of ursodeoxycholic acid with traditional Chinese medicine on biochemical response in patients with primary biliary cholangitis:A realworld cohort study[J]. Chin J Hepatol,2018,26(12):909-915.(in Chinese)陈佳良，杨雪，张群，等．熊去氧胆酸联合中药治疗对原发性胆汁性胆管炎患者生物化学应答的影响:一项基于真实世界的队列研究[J]．中华肝脏病杂志，2018,26(12):909-915.

[27] ZHANG RM,ZHANG T,WU JH,et al. Clinical effect of liversoothing,cholagogic,spleen-strengthening,and bloodactivating therapy combined with ursodeoxycholic acid in treatment of primary biliary cholangitis[J]. Fujian Med J,2019,41(2):27-30.(in Chinese)张如棉，章亭，吴剑华，等．疏肝利胆健脾活血法联合熊去氧胆酸治疗原发性胆汁性胆管炎的临床疗效[J]．福建医药杂志，2019,41(2):27-30.

[28] WU XX,LI X,DANG ZQ,et al. Efficacy of Shugan Lidan Tang combined ursodeoxycholic acid in treating early and midterm primary biliary cirrhosis[J]. Chin J Exp Med Formul,2018,24(12):175-181.(in Chinese)吴秀霞，李鲜，党中勤，等．疏肝利胆汤加减联合熊去氧胆酸治疗早、中期原发性胆汁性肝硬化的临床观察[J]．中国实验方剂学杂志，2018,24(12):175-181.

[29] ZENG WW,WU XJ. Effect of Hugan Zhuyu decoction combined with ursodeoxycholic acid on immunoglobulin and T lymphocyte subsets in patients with primary biliary cirrhosis[J].Chin J Gen Pract,2019,17(3):464-467.(in Chinese)曾武武，吴学杰．护肝逐瘀汤联合熊去氧胆酸对原发性胆汁性肝硬化患者免疫球蛋白及T淋巴细胞亚群的影响[J]．中华全科医学，2019,17(3):464-467.

[30] XIAO LH,HU XY. Clinical effect of Lidan Yanggan prescription combined with ursodeoxycholic acid capsules in treatment of primary biliary cirrhosis[J]. Beijing J Tradit Chin Med,2018,37(6):553-555,561.(in Chinese)肖玲辉，扈晓宇．利胆养肝方联合熊去氧胆酸胶囊治疗原发性胆汁性肝硬化临床观察[J]．北京中医药，2018,37(6):553-555,561.

[31] XIA XY,SHI Y. Efficacy of Qinggan Lidan decoction combined with fenofibrate in the treatment of primary cholangitis with poor response to ursodeoxycholic acid and its effect on Th1/Th2lymphocyte imbalance[J]. Mod J Integr Tradit Chin West Med,2019,28(21):2313-2316,2322.(in Chinese)霞晓燕，石勇．清肝利胆方配合非诺贝特对熊去氧胆酸应答不佳的原发性胆汁性胆管炎应答率及Th1/Th2淋巴细胞失衡的影响[J]．现代中西医结合杂志，2019,28(21):2313-2316,2322.

[32] LIN L,YU XF,CHEN GL. Clinical effect of Qiwei Huaxian decoction combined with ursodeoxycholic acid in treatment of stage II/III primary biliary cirrhosis with spleen deficiency and blood stasis[J]. Tradit Chin Med J,2015,14(5):50-52.(in Chinese)林立，俞晓芳，陈国良．七味化纤汤联合熊去氧胆酸治疗Ⅱ、Ⅲ期脾虚血瘀型原发性胆汁性肝硬化的临床观察[J]．中医药通报，2015,14(5):50-52.

[33] HUANG LY,ZHOU ZH,SUN XH,et al. Clinical efficacy of Biejiaruangan compound tablets in treatment of primary biliary cirrhosis[J]. J Clin Hepatol,2015,31(2):181-184.(in Chinese)黄凌鹰，周振华，孙学华，等．复方鳖甲软肝片治疗原发性胆汁性肝硬化的临床疗效评价[J]．临床肝胆病杂志，2015,31(2):181-184.

[34] JIANG XY,WU WJ,OU Y. Clinical effect of Fuzheng Huayu capsules combined with ursodeoxycholic acid in treatment of primary biliary cholangitis[J]. Med Forum,2019,23(25):3667-3668.(in Chinese)江晓燕，吴文杰，欧旸．扶正化瘀胶囊合并熊去氧胆酸对原发性胆汁性胆管炎的治疗效果观察[J]．基层医学论坛，2019,23(25):3667-3668.

[35] GAO F,XUN J,JIAO JL,et al. Clinical effect of Fuzheng Huayu capsules combined with ursodeoxycholic acid capsules in treatment of primary biliary cirrhosis[J]. J Shanxi Med Coll Contin Educ,2015,25(6):17-19.(in Chinese)高峰，荀健，焦记丽，等．扶正化瘀胶囊联合熊去氧胆酸胶囊治疗原发性胆汁性肝硬化的临床观察[J]．山西职工医学院学报，2015,25(6):17-19.

[36] XI Q,SONG CR,LIU YZ,et al. Study on treatment of primary biliary cirrhosis by Jianpi Huoxue Decocition combined with ursodeoxycholic acid capsules[J]. Mod J Integr Tradit Chin West Med,2016,25(3):242-244,283.(in Chinese)席奇，宋春荣，刘亚珠，等．健脾活血方联合熊去氧胆酸胶囊治疗原发性胆汁性肝硬化的研究[J]．现代中西医结合杂志，2016,25(3):242-244,283.

[37] CHEN XQ,CAO HF. Regulatory effect of Lidan Qushi prescription on peripheral blood T lymphocyte subsets in patients with primary biliary cirrhosis with liver-gallbladder dampheat[J]. J Sichuan Tradit Chin Med,2018,36(11):103-105.(in Chinese)陈秀清，曹海芳．利胆祛湿方对肝胆湿热型原发性胆汁性肝硬化患者外周血T细胞亚群的调节作用[J]．四川中医，2018,36(11):103-105.

[38] JIANG XY,TANG HH,WEI CS,et al. Treatment of 31 cases of primary biliary cholangitis with ruangan decoction combined with ursodeoxycholic acid[J]. Mod Tradit Chin Med,2018,38(6):33-35,39.(in Chinese)姜小艳，唐海鸿，魏春山，等．软肝汤联合熊去氧胆酸治疗原发性胆汁性胆管炎31例[J]．现代中医药，2018,38(6):33-35,39.

[39] YANG L,LI Y,YUAN XX,et al. Effect of Yangyin Tongluo Decoction on primary biliary cholangitis and its influence on cytokines[J]. Chin J Integr Trad West Med Dig,2017,25(9):646-650,655.(in Chinese)杨磊，李莹，袁星星，等．养阴通络汤对原发性胆汁性胆管炎临床疗效及对细胞因子的影响[J]．中国中西医结合消化杂志，2017,25(9):646-650,655.

[40] GAN X,ZHAO XF,LIN H,et al. Efficacy of Qingying Huoxue decoction in treating primary biliary cirrhosis with liver-gallbladder dampness-heat syndrome and effect on Th17/Treg balance in peripheral blood[J]. Chin J Exp Med Formul,2016,22(11):161-164.(in Chinese)甘霞，赵新芳，林红，等．清营活血汤对原发性胆汁性肝硬化肝胆湿热型的疗效以及对外周血Th17/Treg平衡的影响[J]．中国实验方剂学杂志，2016,22(11):161-164.

Relative Articles

[1]	Xiaodong WANG, Yurong ZHANG, Xiaoning ZHU, Ding ZHENG, Jing WANG. Late-onset diaphragmatic hernia after microwave ablation of hepatocellular carcinoma: A case report[J]. Journal of Clinical Hepatology, 2022, 38(8): 1875-1877. doi: 10.3969/j.issn.1001-5256.2022.08.029
[2]	Weike CHU, Xue WU, Peng ZHANG, Jing FENG, Bin NIU, Hui ZHOU, Yuqiang MI, Ping LI. Value of inflammatory biomarkers in predicting the prognosis of early small hepatocellular carcinoma after radiofrequency ablation[J]. Journal of Clinical Hepatology, 2022, 38(4): 843-850. doi: 10.3969/j.issn.1001-5256.2022.04.020
[3]	Sun Bin, Yang XiaoZhen, Xie Fang, Pang LiJun, Chen DeXi, Wang YanJun. Effect of sorafenib combined with transcatheter arterial chemoembolization and radiofrequency ablation on the survival of patients with hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2019, 35(1): 104-108. doi: 10.3969/j.issn.1001-5256.2019.01.019
[4]	Yan JinZhu, Weng Hong, Zhang Chao, Wang Yuan, Yang Jian, Peng XinYu. Clinical effect and safety of percutaneous radiofrequency ablation versus microwave ablation in treatment of hepatocellular carcinoma:a Meta-analysis[J]. Journal of Clinical Hepatology, 2018, 34(5): 1025-1032. doi: 10.3969/j.issn.1001-5256.2018.05.020
[6]	Liang HongYuan, Guo QiYong, Mao XiaoNan, Sun Wei, Zhao Gang, Wang XiHai, Liu Zhen, Wen Feng, Lu ZaiMing. Clinical effect of sequential therapy with transarterial chemoembolization and bipolar-needle radiofrequency ablation in treatment of hepatocellular carcinoma in high-risk locations[J]. Journal of Clinical Hepatology, 2018, 34(7): 1462-1469. doi: 10.3969/j.issn.1001-5256.2018.07.020
[7]	Liu BoZhi, Yuan ZhuHui, Li Wei. A case of large hepatocellular carcinoma treated by transcatheter arterial chemoembolization combined with radiofrequency ablation[J]. Journal of Clinical Hepatology, 2018, 34(7): 1520-1522. doi: 10.3969/j.issn.1001-5256.2018.07.031
[8]	Luo DanDong, Qiao AnYi. Research advances in radiofrequency ablation in treatment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2017, 33(7): 1358-1361. doi: 10.3969/j.issn.1001-5256.2017.07.034
[9]	Wang Peng, Ren WeiDong. Mechanism of radiofrequency ablation in treatment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2017, 33(2): 359-363. doi: 10.3969/j.issn.1001-5256.2017.02.035
[10]	Lu NingNing, Sun Bin, Cui XiongWei, Long Jiang, Gao WenFeng, Zheng JiaSheng. Diagnosis and treatment of subcapsular hemorrhage after liver tumor ablation[J]. Journal of Clinical Hepatology, 2017, 33(12): 2326-2330. doi: 10.3969/j.issn.1001-5256.2017.12.014
[11]	Lu: TianShi, Zou YingHua, Wang Jian, Song Li. Current status of transcatheter arterial chemoembolization combined with radiofrequency ablation in treatment of primary liver cancer[J]. Journal of Clinical Hepatology, 2016, 32(1): 49-55. doi: 10.3969/j.issn.1001-5256.2016.01.007
[12]	Li XinHui, Feng ZhiQiang, Zhang HongYi, Wu Di, Zhao Gang, Wang Xin, Liu Yang. Severe complications after ultrasound-guided percutaneous microwave coagulation therapy for primary hepatic carcinoma[J]. Journal of Clinical Hepatology, 2016, 32(1): 72-75. doi: 10.3969/j.issn.1001-5256.2016.01.011
[13]	Sun Wei, Ding XiaoYan, Chen JingLong. Clinical effect and safety of percutaneous radiofrequency ablation following transcatheter arterial chemoembolization in treatment of primary liver cancer in high-risk locations[J]. Journal of Clinical Hepatology, 2016, 32(12): 2337-2341. doi: 10.3969/j.issn.1001-5256.2016.12.021
[14]	Zhu Ge, Zhao LingLing, Qian Lei, Dong YaBing, Zhao HengJun, Cui JiuWei, Wang NanYa. Influence of serum levels of alkaline phosphatase and gamma-glutamyl transpeptidase on the prognosis of patients with primary liver cancer undergoing radiofrequency ablation[J]. Journal of Clinical Hepatology, 2016, 32(12): 2342-2346. doi: 10.3969/j.issn.1001-5256.2016.12.022
[15]	Liu XiaoXin, Liu YunYi. Radiofrequency ablation for the treatment of hepatocellular carcinoma-rivals, challenges and future developments[J]. Journal of Clinical Hepatology, 2012, 28(4): 245-248.
[16]	Sun JingJuan, Zhao HengJun, Li Wei, Miao FengHua, Wang NanYa. Clinical study of radiofrequency ablation therapy in combination with sorafenib for advanced hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2011, 27(10): 1093-1095+1098.
[17]	Liu JianYong, Lu Wei, Zhou YongHe, Cao HongBo, Zhou GuoQiang, Cao Zhi. The clinical observation of sonographically guided percutaneous microwave coagulation of liver tumors abutting danger areas[J]. Journal of Clinical Hepatology, 2011, 27(4): 375-377.
[18]	Chen MinShan, Liu FuRong. The role of radiofrequency ablation in multidisciplinary treatment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2011, 27(4): 368-371.
[19]	Chinese Society of Liver Cancer (CSLC), Chinese Society of Clinical Oncology(CSCO), Liver Cancer Group, Chinese Society of Hepatology. Guidelines for radiofrequency ablation therapy of liver cancer[J]. Journal of Clinical Hepatology, 2011, 27(3): 236-238+244.
[20]	Liu QuanDa, Zhou NingXin. Treatment of radiofrequency ablation for cirrhotic hypersplenism[J]. Journal of Clinical Hepatology, 2011, 27(2): 119-122.

Supplements(0)

Cited By

Cited by

Periodical cited type(2)

1.	王晓迪，周帆，莫秋萍，赵艳娟. 血小板凝集功能、纤维蛋白原水平与急性ST段抬高型心肌梗死患者经皮冠状动脉介入术后发生主要不良心脏事件相关性分析. 临床军医杂志. 2023(03): 301-303+307 .
2.	邹海虹，林宇，白云雪，聂益军. 不同泌尿外科疾病凝血及血小板参数指标的对比研究. 实验与检验医学. 2023(06): 761-763+768 .

Other cited types(0)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (1565) PDF downloads(300)

Biochemical response and integrated traditional Chinese and Western medicine therapy for primary biliary cholangitis

DOI: 10.3969/j.issn.1001-5256.2020.01.004